Swiss drug major Novartis (NOVN: VX) revealed this morning (August 15) that the Australian Therapeutic Goods Administration (TGA) has added Bexsero, a multi-component meningococcal B (MenB) vaccine (recombinant, adsorbed) suspension for injection 0.5ml pre-filled syringe, to the Australian Register of Therapeutic Goods (ARTG) for use in individuals from two months of age and older.
Bexsero is the first and only broad coverage vaccine to help protect all age groups against MenB disease, including infants who are at the greatest risk of infection, said Novartis. Andrew Weiss, an analyst at Vontoble, has previously said the vaccine could achieve peak sales of $2 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze